Table 3.
Clinicopathologic characteristics of HER2 status-HERmark concordant and discordant groups
| Concordant negative | Concordant positive | Discordant low | Discordant high | |||||
|---|---|---|---|---|---|---|---|---|
| HER2 -, H2T low | HER2 +, H2T high | HER2 +, H2T low | HER2 -, H2T high | |||||
| Parameter | No. | % | No. | % | No. | % | No. | % |
| Tumor size (cm) | ||||||||
| <2 | 45 | 51% | 30 | 49% | 9 | 47% | 6 | 43% |
| >2 | 43 | 49% | 31 | 51% | 10 | 53% | 8 | 57% |
| Tumor grade | ||||||||
| Grade 1 and Grade 2 | 41 | 54% | 10 | 19%* | 6 | 40% | 8 | 62% |
| Grade 3 | 35 | 46% | 43 | 81% | 9 | 60% | 5 | 38% |
| Stage at initial diagnosis | ||||||||
| I and II | 73 | 83% | 40 | 65% | 14 | 74% | 8 | 47% |
| III and IV | 15 | 17% | 22 | 35%* | 5 | 26% | 9 | 53% |
| Nodal status at diagnosis | ||||||||
| Node negative | 40 | 55% | 15 | 28% | 7 | 47% | 3 | 25% |
| Node positive | 33 | 45% | 38 | 72% | 8 | 53% | 9 | 75% |
| Hormone receptor (ER/PR) status | ||||||||
| Negative | 19 | 21% | 23 | 37%* | 6 | 32% | 4 | 24% |
| Positive | 72 | 79% | 40 | 63%* | 13 | 68% | 13 | 76% |
* P <0.05. Fisher exact test was performed for each parameter between two concordant groups, or, between two discordant groups. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; H2T, quantitative total HER2 expression by HERmark; PR, progesterone receptor.